Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome — SOS-COVID19  

Covid19 Clinical Trial

Official title: Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.

Status Terminated

Clinical Trial Summary

The COVID-19 pandemic has already overwhelmed the sanitary capacity. Additional therapeutic arsenals, albeit untested in the given context but previously proven to be efficacious in a related clinical context, that could reduce the morbidity rate are urgently needed. A decrease of Heart Rate Variability (HRV) is a validated bad prognosis marker in sepsis and acute respiratory distress syndrome. In contrast, auricular vagus nerve stimulation was proven not only to increase HRV values in healthy Humans, but also to reduce sepsis and increase survival, both significantly, in experimental models. Moreover, the heavy viral infection within the brainstem of deceased patients suggests that the neuroinvasive potential of SARS-CoV2 is likely to be partially responsible for COVID-19 acute respiratory failure and may bear relevance in tailoring future treatment modalities. Interestingly, the vagus nerve (or tenth cranial nerve) connects bidirectionally the brainstem to various internal organs including the lung and to one external organ, namely, the outer ear. Hence, the impact of auricular vagus nerve stimulation through semi-permanent needles will be studied, mostly used so far for pain alleviation, on the outcome of COVID-19 inpatients within 15 days.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Coronavirus Infections
• Covid19
• SARS-CoV Infection
• Severe Acute Respiratory Syndrome

• NCT number: NCT04341415
• Study type: Interventional
• Source: Fondation Ophtalmologique Adolphe de Rothschild
• Status: Terminated
• Phase: N/A
• Start date: April 9, 2020
• Completion date: January 15, 2021